Ultime notizie per Ocular Therapeutix (NASDAQ:OCUL) Azioni

Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix Inc

Oculis Holding AG

OCULUS VISIONTECH INC by Oculus Visiontech, Inc.

Oculus VisionTech Inc

WIIM

OCUL

Ocular Therapeutix shares are trading higher after Scotiabank Initiated coverage on the stock with a Sector Outperform rating and announced a $22 price target.

Scotiabank analyst Greg Harrison initiates coverage on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Sector Outperform rating and announces Price Target of $22.

News

Price Target

Initiation

Analyst Ratings

Scotiabank Initiates Coverage On Ocular Therapeutix with Sector Outperform Rating, Announces Price Target of $22

HC Wainwright &amp; Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and maintains $14 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $14 Price Target

<ul>
<li>SOL-1 is now expected to be enrolled and fully randomized by year-end 2024</li>
<li>Topline clinical data from SOL-1 are now expected in&nbsp;Q4&nbsp;2025</li>
</ul>

Ocular Therapeutix Fast-Tracks SOL-1 Registrational Trial For Wet AMD, Topline Data Expected In Late 2025

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Outperform and lowers the price target from $18 to $17.

Baird Maintains Outperform on Ocular Therapeutix, Lowers Price Target to $17

Biotech

Earnings

Guidance

Health Care

General

Ocular Therapeutix' Cash Balance Of $459.7M As Of June 30, 2024, Expected to Fund Operations Into 2028

Ocular Therapeutix Q2 2024 GAAP EPS $(0.26) Misses $(0.22) Estimate, Sales $16.441M Beat $15.824M Estimate

Ocular Therapeutix Has Received FDA Written Response That Phase 3 Sol-r Trial Is Appropriate For Use As The Company's Second Adequate And Well Controlled Study Of Axpaxli (Axitinib Intravitreal Implant, Also Known As OTX-TKI) For Wet Age-related Macular Degeneration

Analysts' ratings for Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $14.0, along with a high estimate of $22.00 and a low estimate of $7.00. This current average represents a 3.45% decrease from the previous average price target of $14.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722535538_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Ocular Therapeutix's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Tara Bancroft</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Tara Bancroft</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$7.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ocular Therapeutix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ocular Therapeutix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ocular Therapeutix's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ocular Therapeutix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Ocular Therapeutix</h2>
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
<h3>Ocular Therapeutix: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Ocular Therapeutix's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 10.47%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ocular Therapeutix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -438.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ocular Therapeutix's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -25.99%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -16.4%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Ocular Therapeutix adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock

Ocular Therapeutix Enrolls First Patients In Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>, "Ocular", the "Company")))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that a late-breaking abstract related to the Phase 1 HELIOS study of AXPAXLI (axitinib intravitreal implant) for non-proliferative diabetic retinopathy (NPDR) was accepted for presentation at the 42nd American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held July 17-20 in Stockholm, Sweden.

Ocular Therapeutix To Present Late-Breaking Abstract Of HELIOS Study At 42nd ASRS Annual Scientific Meeting

Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Overweight and maintains $15 price target.

Piper Sandler Maintains Overweight on Ocular Therapeutix, Maintains $15 Price Target

Shares of Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) fell sharply during Thursday's session <a href="https://www.benzinga.com/news/earnings/24/06/39411910/jabil-tops-q3-estimates-ceo-highlights-strategic-growth-in-ai-datacenters-and-ev-markets">following third-quarter results</a>.
Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22).
Jabil shares dipped 7.8% to $116.37 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares jumped 222.8% to $1.48 after the company said it expects the pending acquisition of Spetner Associates to close in the second half of 2024, projecting it to increase annualized revenue to approximately $28 million.</li>
<li>Griid Infrastructure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRDI#NASDAQ">GRDI</a>) climbed 89.3% to $1.48 after falling more than 10% on Tuesday.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) gained 89% to $2.58 after the company said it expects first customer deliveries of the i300 in the fourth quarter and anticipates selling over 5,000 units in the fiscal year ending September 30, 2025.</li>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) shares climbed 60.5% to $0.6279. Reliance Global Group announced major enhancement of capital structure following cashless exercise of warrants.</li>
<li>Allurion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) gained 50% to $1.598. Allurion announced publication of new data demonstrating lean mass gains in patients experiencing 14% weight loss.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) rose 43% to $0.1702 after jumping 19% on Tuesday.</li>
<li>Soluna Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) gained 23.3% to $5.96.</li>
<li>Femasys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) rose 22% to $1.1650 after receiving CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products.</li>
<li>Molecular Partners AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 21.1% to $9.63 after gaining 9% on Tuesday.</li>
<li>Surf Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NASDAQ">SRFM</a>) jumped 20.6% to $0.3850.</li>
<li>ToughBuilt Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLT#NASDAQ">TBLT</a>) gained 20.2% to $3.75.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) surged 19.7% to $1.1303. MicroCloud Hologram entered into convertible note purchase agreements with investors for $28 million on June 18.</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) shares climbed 19.2% to $0.0877after falling around 5% on Tuesday.</li>
<li>NanoViricides, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NASDAQ">NNVC</a>) gained 16.5% to $1.91. Nanoviricides reported that the ultra-broad-spectrum antiviral NV-387, a Phase 2 Stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected influenza H3N2 mouse model.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) rose 16.4% to $2.47.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) gained 16% to $6.36 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) jumped 15.3% to $5.95.</li>
<li>Ranpak Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) climbed 13.7% to $6.49.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 13.6% to $7.08 after the company announced insurance coverage of ANKTIVA across multiple states with first commercial doses administered.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) gained 12.2% to $19.81 after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also the company announced that the second and third required PPQ batches are now scheduled.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) rose 11.4% to $3.92</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) gained 11.3% to $12.91.</li>
<li>Himax Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>) jumped 11.1% to $8.23</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) surged 11% to $0.5849</li>
<li>Nexalin Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) gained 10% to $1.1450. Nexalin Technology shares jumped around 38% on Tuesday after the company was awarded a US patent on &#8216;Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimers and Dementia.&#8217;</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares climbed 7.8% to $17.45. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 7% to $982.60 after Elon Musk indicated the company will provide server racks for the supercomputer that xAI is building.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) rose 5% to $162.36.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) fell 43.7% to $0.1993. Trevena announced preclinical TRV045 data for long-term analgestic effect in prelinical model of neuropathic pain. Also, the company announced TRV045 results provided director for additional NIH-initiated studies in epilepsy prevention and treatment.</li>
<li>Kaival Brands Innovations Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares declined 33.5% to $2.99 after gaining 8% on Tuesday.</li>
<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) fell 29% to $1.10. Sonnet BioTherapeutics announced exercise of warrants for gross proceeds of $3.4 million.</li>
<li>Tempest Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) declined 25% to $2.1208. The company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120).</li>
<li>Nikola Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) declined 23.6% to $0.3672. Nikola announced 1-for-30 reverse stock split approved by board.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) shares fell 23.5% to $1.37. La Rosa Holdings shares jumped 72% on Tuesday after the company entered a non-binding letter of intent to acquire a controlling interest in Red Door Title.</li>
<li>SYLA Technologies Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYT#NASDAQ">SYT</a>) dipped 21.7% to $1.70.</li>
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares dipped 21% to $0.6721 after the company announced a $2.5 million registered direct offering of 6.130 million shares at $0.41 per share.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) fell 20.9% to $72.55.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) tumbled 20.3% to $0.1910 after jumping 82% on Tuesday.</li>
<li>DermTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) fell 19.4% to $0.1176.</li>
<li>Dunxin Financial Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXF#NASDAQ">DXF</a>) shares fell 19.4% to $0.1728 after dipping 17% on Tuesday.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) fell 15.1% to $25.76 amid post-IPO volatility.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) declined 15% to $2.2991 after B of A Securities downgraded the stock from Neutral to Underperform.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares fell 13.7% to $0.2150. SRIVARU, last week, announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) fell 12.2% to $1.8602. Actelis Networks shares jumped 84% on Tuesday after the company announced an agreement to serve as Carahsoft&#8217;s public sector distributor.</li>
<li>Jasper Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) declined 10.1% to $20.84. Jasper Therapeutics announced appointment of Svetlana Lucas Ph.D., to its Board of Directors.</li>
<li>GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) declined 6.5% to $84.02 after the company reported mixed fourth-quarter financial results.</li>
<li>Nayax Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) fell 6.1% to $21.23.</li>
<li>Vanda Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) fell 5% to $6.03 after the company&#8217;s board determined that recent takeover proposals were not in its best interests.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39411935/this-skyworks-solutions-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday">This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday</a>

Intraday Update

Markets

Movers

Trading Ideas

ALUR

APLD

ASNS

BILI

DMTK

ESPR

FEMY

GRDI

HIMX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HROW

IBRX

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

KAVL

LOBO

LRHC

MBIO

MGOL

MOLN

NKLA

NLSP

NNVC

NYAX

PACK

PRST

RELI

SLNH

SMCI

SONN

SRFM

SVMH

TBLT

Tempest Therapeutics, Inc. - Common Stock

TPST

TRVN

VNDA

ZAPP

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday.
Shares of KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) rose during Thursday's session as the company posted better-than-expected earnings and sales results for its <a href="https://www.benzinga.com/news/earnings/24/06/39410316/kb-home-analysts-boost-their-forecasts-after-upbeat-q2-results">second quarter on Tuesday</a>.
KB Home reported quarterly earnings of $2.15 per share, which beat the analyst consensus estimate of $1.78. Quarterly sales came in at $1.71 billion, which beat the analyst consensus estimate of $1.651 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
KB Home shares gained 4.2% to $70.91 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) shares climbed 16% to $6.36 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) jumped 15.3% to $5.95.</li>
<li>Ranpak Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) rose 13.7% to $6.49.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) gained 13.6% to $7.08 after the company announced insurance coverage of ANKTIVA across multiple states with first commercial doses administered.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares jumped 12.2% to $19.81 after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also the company announced that the second and third required PPQ batches are now scheduled.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) climbed 11.4% to $3.92</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) rose 11.3% to $12.91.</li>
<li>Himax Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>) surged 11.1% to $8.23</li>
<li>Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) gained 7.9% to $166.36 after the company announced the launch of Globant GUT.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares jumped 7.8% to $17.45. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) climbed 7% to $982.60 after Elon Musk indicated the company will provide server racks for the supercomputer that xAI is building.</li>
<li>Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) gained 6.7% to $304.41 after the company posted quarterly results.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) rose 6.2% to $20.18.</li>
<li>WestRock Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRK#NYSE">WRK</a>) rose 5.6% to $52.48.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) gained 5% to $162.36.</li>
<li>Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) climbed 4.5% to $22.35.</li>
<li>Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) rose 4.1% to $65.76 after the company announced results from an interim analysis of a Phase 3 trial, showing Lenacapavir demonstrated 100% efficacy for HIV prevention and superiority to daily Truvada.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39410338/top-4-consumer-stocks-that-may-keep-you-up-at-night-this-month">Top 4 Consumer Stocks that May Keep You Up At Night This Month</a>

GILD

GLOB

KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Wolfe Research analyst Mike Polark upgraded the rating for iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) from Peer Perform to Outperform and announced a price target of $115. iRhythm Technologies shares gained 2.5% to close at $98.16 on Wednesday. <a href="https://www.benzinga.com/quote/IRTC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst John Pancari upgraded Bread Financial Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) from Underperform to In-Line and boosted the price target from $42 to $45. Bread Finl shares gained 0.5% to close at $40.84 on Tuesday. <a href="https://www.benzinga.com/quote/BFH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen analyst Tara Bancroft upgraded the rating for Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) from Hold to Buy, while raising the price target from $7 to $11. Ocular Therapeutix shares fell 0.2% to settle at $5.49 on Tuesday. See how other analysts view this stock. <a href="https://www.benzinga.com/quote/OCUL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Heather Balsky upgraded the rating for TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) from Neutral to Buy and announced a price target of $92. TransUnion shares slipped 0.01% to close at $71.31 on Tuesday. <a href="https://www.benzinga.com/quote/TRU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities analyst Craig Ellis upgraded Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) from Neutral to Buy, while increasing the price target from $96 to $130. Skyworks Solutions shares rose 0.2% to settle at $106.46 on Tuesday. <a href="https://www.benzinga.com/quote/SWKS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39408372/sacks-parente-golf-and-2-other-stocks-under-1-insiders-are-buying">Sacks Parente Golf And 2 Other Stocks Under $1 Insiders Are Buying</a>

Analyst Color

Upgrades

IRTC

SWKS

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised the price target for Bread Financial Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) from $42 to $45. Evercore ISI Group analyst John Pancari upgraded the stock from Underperform to In-Line. Bread Financial shares gained 0.5% to close at $40.84 on Tuesday. <a href="https://www.benzinga.com/quote/BFH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen raised the price target for Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) from $7 to $11. TD Cowen analyst Tara Bancroft upgraded the stock from Hold to Buy. Ocular Therapeutix shares fell 0.2% to close at $5.49 on Tuesday. <a href="https://www.benzinga.com/quote/OCUL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group increased KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) price target from $78 to $86. Evercore ISI Group analyst Stephen Kim maintained an Outperform rating. KB Home shares fell 2.1% to close at $68.04 on Tuesday. <a href="https://www.benzinga.com/quote/KBH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut the price target for Shattuck Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) from $28 to $16. HC Wainwright &amp; Co. analyst Joseph Pantginis maintained a Buy rating. Shattuck Labs shares fell 7.8% to close at $4.59 on Tuesday. <a href="https://www.benzinga.com/quote/SSTK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities slashed Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) price target from $2.9 to $2.5. B of A Securities analyst Jason Zemansky downgraded the stock from Neutral to Underperform. Esperion Therapeutics shares fell 5.2% to close at $2.72 on Tuesday. <a href="https://www.benzinga.com/quote/ESPR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) price target from $277 to $316. Baird analyst Mark Marcon maintained an Outperform rating. Workday shares fell 2.2% to close at $207.69 on Tuesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein boosted the price target for Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) from $150 to $200. Bernstein analyst Mark Li maintained an Outperform rating. Taiwan Semiconductor Manufacturing shares gained 1.4% to close at $179.69 on Tuesday. <a href="https://www.benzinga.com/quote/TSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc increased Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) price target from $475 to $540. Keybanc analyst Justin Patterson maintained an Overweight rating. Meta Platforms shares fell 1.4% to close at $499.49 on Tuesday. <a href="https://www.benzinga.com/quote/META/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) price target from $66 to $69. Keefe, Bruyette &amp; Woods analyst David Konrad maintained a Market Perform rating. Citigroup shares gained 1.2% to close at $60.78 on Tuesday. <a href="https://www.benzinga.com/quote/C/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) price target from $160 to $187. B of A Securities analyst Christopher Nardone maintained a Buy rating. Crocs shares fell 0.2% to close at $159.42 on Tuesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/06/39405641/hewlett-packard-enterprise-accenture-and-3-stocks-to-watch-heading-into-thursday">Hewlett Packard Enterprise, Accenture And 3 Stocks To Watch Heading Into Thursday</a>

CROX

STTK

WDAY

Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday

Ocular Therapeutics shares are trading higher after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.

TD Cowen analyst Tara Bancroft upgrades Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) from Hold to Buy and raises the price target from $7 to $11.

TD Cowen Upgrades Ocular Therapeutix to Buy, Raises Price Target to $11

Shares of AMMO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) fell sharply during Friday's session <a href="https://www.benzinga.com/quote/POWW/earnings">following fourth-quarter results</a>.
AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for a loss of 1 cent per share. The company reported quarterly sales of $40.42 million topping estimates of $37.90 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
AMMO shares dipped 19.1% to $2.0306 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares jumped 345% to $6.06.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) gained 150% to $0.3852 after the company announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) surged 42.5% to $5.16.</li>
<li>FOXO Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NASDAQ">FOXO</a>) shares gained 29% to $0.3092 after the company announced it entered into share exchange agreements with Rennova Health.</li>
<li>Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) surged 29% to $0.4528.</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) gained 25.7% to $2.15.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) rose 23.4% to $3.36.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) gained 20% to $1.4599 as the company announced iRWD customer data license agreement with a leading U.S.-based global clinical trial design and software company.</li>
<li>Can-Fite BioPharma Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANF#NYSE">CANF</a>) jumped 17.9% to $4.28.</li>
<li>Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) rose 15.6% to $45.29. Disc Medicine announced a $178 million underwritten offering of 4.944 million shares at $36 per share.</li>
<li>Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) rose gained 14.3% to $524.39 following better-than-expected second-quarter earnings and strong guidance.</li>
<li>RenovoRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) surged 14.3% to $1.2001.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) gained 14.1% to $5.75 as the company highlighted AXPAXLI SOL-1 enrollment and plans repeat dosing study in wet AMD.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 14% to $0.1836 after dipping 17% on Thursday.</li>
<li>VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) gained 9.9% to $4.32. VinFast Auto anticipates sustained growth for next five years and approaching break-even point.</li>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) rose 9.9% to $21.11. UBS analyst Steven Fisher upgraded Tutor Perini from Neutral to Buy and raised the price target from $14 to $27.</li>
<li>Willis Lease Finance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) gained 6.4% to $64.99.</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) gained 5.5% to $61.22 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $70 to $80.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares dipped 43.3% to $116.47 after announcing a $3.5 billion private placement.</li>
<li>Nexalin Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares fell 33.3% to $0.9192 after jumping 121% on Thursday. Nexalin Technology recently announced regulatory approval of Gen-2 15mA neurostimulation device by Brazilian Health Regulatory Agency.</li>
<li>IN8bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) dipped 31.1% to $1.1598 after the company presented data from its Phase 1 trial of INB-100 showing 100% of treated leukemia patients achieved durable complete remission at 1 year.</li>
<li>Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) fell 28.1% to $1.3599 after the company announced the pricing of a $11 million public offering of 7,116,547 shares at $1.35 per share and pre-funded warrants.</li>
<li>Kyverna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) dipped 24.8% to $10.88.</li>
<li>Rezolute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) shares fell 24.3% to $3.90 after the company announced pricing of public offering of $60 million of common stock and pre-funded warrants.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) dipped 20.2% to $0.3302.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) fell 20.2% to $5.66. The company announced completion of ADS ratio change.</li>
<li>NanoViricides, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NASDAQ">NNVC</a>) fell 19.3% to $2.08</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 19.2% to $0.7141 after jumping over 35% on Thursday.</li>
<li>Ostin Technology Group Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) fell 19.2% to $0.4020 after jumping 24% on Thursday.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares fell 18.6% to $225.60 after the company reported mixed first-quarter financial results.</li>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) declined 15.3% to $0.26.</li>
<li>Bandwidth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) fell 13.1% to $16.07. Morgan Stanley analyst Meta Marshall downgraded Bandwidth from Equal-Weight to Underweight and lowered the price target from $18 to $15.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) dipped 12.5% to $10.99 as the company announced initial clinical data from Phase 1/2 RESET-Myositis and RESET-SLE trials of CABA-201.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) fell 10.5% to $6.11.</li>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) dipped 10% to $28.36.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) fell 9.7% to $13.59.</li>
<li>PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) fell 9.6% to $17.23. Truist Securities analyst Barry Jonas maintained PENN Entertainment with a Buy and raised the price target from $23 to $25.</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) fell 9.6% to $51.65.</li>
<li>MSC Industrial Direct Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) shares declined 8.3% to $77.48 after the company reported preliminary third-quarter financial results below estimates and cut its FY24 adjusted operating margin.</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell 7.7% to $39.82 as the company announced the pricing of public offering of common stock and pre-funded warrants.</li>
<li>WESCO International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) fell 7.1% to $161.79.</li>
<li>Carnival plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUK#NYSE">CUK</a>) fell 6.7% to $13.89.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) fell 5.7% to $14.23.</li>
<li>Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) fell 5.6% to $18.93</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39331763/dell-palo-alto-networks-and-2-other-stocks-insiders-are-selling">Dell, Palo Alto Networks And 2 Other Stocks Insiders Are Selling</a>

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

FOXO

GANX

INAB

IONM

IRON

JFBR

KITT

KYTX

LGVN

NAAS

NVAX

ONMD

PENN

POWW

RARE

RNXT

RZLT

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session

An announcement from Ocular Therapeutix (OCUL) is now available. Ocular Therapeutix, Inc. has appointed its seasoned executive, Donald Notman, as C...

Ocular Therapeutix Appoints Donald Notman as COO

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Ocular Therapeutix (OCUL – Research Report), with a price targ...

Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler

An update from Ocular Therapeutix ( ($OCUL) ) is now available. Ocular Therapeutix, Inc. has recently expanded its 2019 Inducement Stock Incentive ...

Ocular Therapeutix Expands Stock Incentive Plan for Employees

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

Ocular Therapeutix announces accelerated timelines for trial of AXPAXLI in wet AMD

Analyst Tazeen Ahmad of Bank of America Securities maintained a Buy rating on Ocular Therapeutix (OCUL – Research Report), retaining the price targ...

Buy Rating on Ocular Therapeutix: Accelerated Phase 3 Trial Enrollment and Promising 2025 Outlook

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Ocular Therapeutix (OCUL – Research Report). The associated price target rem...

Ocular Therapeutix's Promising Clinical Advancements and Strategic Trials Drive Buy Rating

Robert W. Baird analyst Colleen M. Kusy has maintained their bullish stance on OCUL stock, giving a Buy rating yesterday. Colleen M. Kusy's rating ...

Optimistic Buy Rating for Ocular Therapeutix Amid Accelerated SOL-1 Study Progress

Press Releases

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Comments

Ocular Therapeutix

Notizie

Ultime notizie per Ocular Therapeutix (NASDAQ:OCUL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO